Bethyl Laboratories News and Press

News
Fortis Life Sciences Acquires Bethyl Laboratories

Fortis Life Sciences Acquires Bethyl Laboratories

Fortis Life Sciences, a life sciences company offering products and solutions for the life sciences industry, has acquired the premium antibody company Bethyl Laboratories. Based in Montgomery, Texas, Bethyl Laboratories has a long history of offering the highest quality primary and secondary antibodies to its customers, as well as other protein detection reagents. Bethyl Laboratories is well known for industry leading performance and the highest standards in antibody validation, and prior to the acquisition by Fortis, had successfully operated as a private, family-owned, and operated business for nearly 50 years.

Mar 17, 2021
Press Release
Biocare Medical and Bethyl Laboratories Announces the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications

Biocare Medical and Bethyl Laboratories Announces the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications

August, 4 2020 – Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.

Aug 4, 2020
Press Release
Fluidigm Press Release: New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System

Fluidigm Press Release: New Collaboration with Bethyl Laboratories Expands Antibody Offerings for Hyperion Imaging System

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a collaboration with Bethyl Laboratories to provide broader verified antibody access for researchers using Fluidigm’s Imaging Mass Cytometry™ (IMC™) technology.

Jun 17, 2020